

Appl. No.
Filed

: 09/720,041
: April 2, 2001

Although no fees are believed to be due at this time, please charge any fees, including any fees for extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: October 5, 2001

By: _____

Ginger R. Dreger
Ginger R. Dreger
Registration No. 33,055
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(415) 954-4114

In the Specification:

Please replace the paragraph beginning at page 4, line 33, with the following rewritten paragraph:

--In another embodiment the invention consists in a whey protein hydrolysate containing one or more bioactive peptides selected from the group consisting of AFE, LFSH (SEQ ID NO: 1), ILKEKH (SEQ ID NO: 2), LIVTQ (SEQ ID NO: 3), MKG, LDIQK (SEQ ID NO: 4), VF, ALPMH (SEQ ID NO: 5), VTSTAV (SEQ ID NO: 6), LHLPLP (SEQ ID NO: 7), LVYFPFGPIPNLQNP (SEQ ID NO: 8), and LFRQ (SEQ ID NO: 9)--

The table on page 16 has been amended as follows:

TABLE 3: ACE-I Peptides and their Activities

Peptide Sequence ^a	Origin	Activity ^b (IC ₅₀ in mg L ⁻¹)	Similarity to known ACE-I Peptides
AFE (Ala-Phe-Glu)	PP ^D 3(129-131)	20	
LFSH (Leu-Phe-Ser-His) (SEQ ID NO: 1)	PP3(125-128)	30	
ILKEKH (Ile-Leu-Lys-Glu-Lys-His) (SEQ ID NO: 2)	PP3(71-76)	20	
LIVTQ (Leu-Ile-Val-Thr-Gln) (SEQ ID NO: 3)	β-LG ^e (1-5)	17	
MKG (Met-Lys-Gly)	β-LG(7-9)	24	
LDIQK ^c (Leu-Asp-Ile-Gln-Lys) (SEQ ID NO: 4)	β-LG(10-14)	17	β-LG (9-14)
VF (Val-Phe)	β-LG(81-82)	19	
ALPMH (Ala-Leu-Pro-Met-His) (SEQ ID NO: 5)	β-LG(142-146)	12	β-LG (142-148)
VTSTAV (Val-Thr-Ser-Thr-Ala-Val) (SEQ ID NO: 6)	GMP ^f (59-64)	30	
LHLPLP	β-CN ^g (133-138)	7	

(Leu-His-Leu-Pro-Leu-Pro) (SEQ ID NO: 7)			
LVYFPFGPIPNLSLPQNIPP (Leu-Val-Tyr-Pro-Phe-Pro- Gly-Pro-Ile-Pro-Asn-Ser- Leu-Pro-Gln-Asn-Ile-Pro- Pro) (SEQ ID NO: 8)	β -CN (58-76)	19	β -CN(74-76)
LFRQ (Leu-Phe-Arg-Glu) (SEQ ID NO: 9)	α_{s1} -CN(136-139)	17 ^h	

In the Claims:

Claims 19, 26, and 29 have been amended as follows:

Claim 19. (Once amended) A process as claimed in claim 6 or in any claim dependent from claim 6 wherein one or more of the bioactive peptides in the resulting hydrolysate is selected from the group consisting of AFE, LFSH (SEQ ID NO: 1), ILKEKY (SEQ ID NO: 2), LIVTQ (SEQ ID NO: 3), MKG, LDIQK (SEQ ID NO: 4), VF, ALPMH (SEQ ID NO: 5), VTSTAV (SEQ ID NO: 6), LHLPLP (SEQ ID NO: 7), LVYFPFGPIPNLSLPQNIPP (SEQ ID NO: 8) and LFRQ (SEQ ID NO: 9).

Claim 26. (Once amended) A product as claimed in any one of claims 20 to 25 wherein one or more of the bioactive peptides is selected from the group consisting of AFE, LFSH (SEQ ID NO: 1), ILKEKH (SEQ ID NO: 2), LIVTQ (SEQ ID NO: 3), MKG, LDIQK (SEQ ID NO: 4), VF, ALPMH (SEQ ID NO: 5), VTSTAV (SEQ ID NO: 6), LHLPLP (SEQ ID NO: 7), LVYFPFGPIPNLSLPQNIPP (SEQ ID NO: 8) and LFRQ (SEQ ID NO: 9).

Claim 29. (Once amended) Any one or any combination of two or more of the bioactive peptides selected from the group consisting of AFE, LFSH (SEQ ID NO: 1), ILKEKH (SEQ ID NO: 2), LIVTQ (SEQ ID NO: 3), MKG, LDIQK (SEQ ID NO: 4), VF, ALPMH (SEQ ID NO: 5), VTSTAV (SEQ ID NO: 6), LHLPLP (SEQ ID NO: 7), LVYFPFGPIPNLSLPQNIPP (SEQ ID NO: 8) and LFRQ (SEQ ID NO: 9).